Obesity fuels leukemia, but a combo using popular weight-loss drugs may stop it, IU-led study finds

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

The ASCERTAIN-V phase I/II clinical trial, which evaluated the first all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive induction chemotherapy, demonstrated favorable response rates and survival with expected myelosuppressive effects.

June 18, 2026

Vol.52 No.24

Clinical Roundup

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.

June 18, 2026

Vol.52 No.24

Drugs & Targets

FDA grants Fast Track designation for STX-0712 for r/r CMML

FDA has granted Fast Track designation to STX-0712, an investigational therapy in development for the treatment of relapsed or refractory chronic myelomonocytic leukemia.

May 29, 2026

Vol.52 No.21

Clinical Roundup

“Forever chemicals” may be linked to childhood leukemia, UC Irvine study finds

Early exposure to PFAS, a group of widely used compounds known as “forever chemicals,” was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to researchers at the University of California, Irvine Joe C. Wen School of Population & Public Health.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Cell-free DNA offers early warning for bloodstream infections in children with leukemia, St. Jude-led study finds

A study led by researchers at St. Jude Children’s Research Hospital shows that microbial cell-free DNA sequencing can predict bloodstream infections in children with leukemia days before the infection is apparent.

March 06, 2026

Vol.52 No.09

In Brief

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab (Blincyto) in treating one of the rarest and most aggressive forms of leukemia.

February 20, 2026

Vol.52 No.07

Obesity fuels leukemia, but a combo using popular weight-loss drugs may stop it, IU-led study finds

YOU MAY BE INTERESTED IN

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

FDA grants Fast Track designation for STX-0712 for r/r CMML

“Forever chemicals” may be linked to childhood leukemia, UC Irvine study finds

Cell-free DNA offers early warning for bloodstream infections in children with leukemia, St. Jude-led study finds

WVU Cancer Institute first in the world to treat ultra-rare leukemia using novel subcutaneous immunotherapy

Renew today!

Subscriber content

Never miss an issue!

Login